Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe.
Annals of oncology : official journal of the European Society for Medical Oncology·2022
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.
Cancer treatment reports·1987
IV melphalan in children.
Cancer treatment reports·1987
Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
Cancer treatment reports·1987
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports·1987
Doxorubicin distribution in human breast cancer.
Cancer treatment reports·1987
Phase I study of echinomycin.
Cancer treatment reports·1987
Comparative safety of PICC-ports and chest ports in oncology: A monocentric retrospective cohort study.
The journal of vascular access·2026
Combinatorial effects of curcumin, morin, and phyllanthin in MDA-MB-231 and MCF-7 breast cancer cell lines.
Indian journal of pharmacology·2026
Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.
Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Cost-effectiveness analysis of liposomal Irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece.
Expert review of pharmacoeconomics & outcomes research·2026